CVM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

CVM

47.2
AI Score
VS
CVM Wins

MRNA

38.7
AI Score

Investment Advisor Scores

CVM

47score
Recommendation
HOLD

MRNA

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CVM MRNA Winner
Revenue 77,403 1.85B MRNA
Net Income -3.11M -1.96B CVM
Net Margin -4023.4% -106.3% MRNA
Operating Income -14.26M -2.07B CVM
ROE -33.9% -28.7% MRNA
ROA -13.1% -14.6% CVM
Total Assets 23.74M 13.47B MRNA
Cash 10.58M 1.20B MRNA
Current Ratio 1.41 3.62 MRNA
Free Cash Flow -17.90M -2.86B CVM

Relative Price Performance (Last 90 Days)

CVM 1M: -30.4% · 3M: -22.7% MRNA 1M: +2.2% · 3M: +265.4%

Current Technical Phase

CVM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.6%), weak momentum, RSI 34

RSI (14): 34.2 · Price: $1.19

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53

RSI (14): 52.5 · Price: $231.35

Fundamentals Snapshot

Metric CVM MRNA
Market Cap — —
Forward P/E -0.2 -53.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.6% 0.3%
Gross Margin -518.1% -0.4%
Operating Margin 0.0% -0.8%
EPS -1.57 -6.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CVM is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.